Bendamustine
Treanda · Alkylator
Tumor lysis-mediated AKI is the principal risk; TMA is rare.
PRETMALYTE
ModerateOpen →
BCMA CAR-T cell therapy
Ciltacabtagene autoleucel
Carvykti · CILT
A high-avidity BCMA CAR-T sharing ide-cel's CRS-driven prerenal AKI — with a signature delayed parkinsonism not to be mistaken for uremia.
ModerateBCMA CAR-T cell therapy · approved 2022
Relapsed or refractory multiple myeloma (after >=1 prior line including a proteasome inhibitor and an immunomodulatory agent, lenalidomide-refractory, in the expanded indication)
Signature kidney injury
Prerenal / Hemodynamic AKI
CRS-associated AKI mirrors the BCMA CAR-T class (roughly 5-30% across cohorts, mostly mild) and generally reverses with supportive care. A distinct, non-renal signature toxicity is a delayed movement-and-neurocognitive (parkinsonism-like) syndrome.
Source: Berdeja et al., Lancet 2021
Toxicity fingerprint
Tap a signature to trace where it strikes the nephron.
Incidence not quantified
SeverityModerate
ReversibilityReversible
Evidence0 refs
Nephron map
Vasculature / EndotheliumGlomerular & peritubular capillaries
Proximal Tubule
Distal Tubule / Collecting Duct
Tubular Lumen
Prerenal / Hemodynamic AKI
Renal hypoperfusion from capillary leak and cytokine storm — IL-2 and CAR-T cytokine release syndrome.
Mechanism of kidney injury
The same CRS-driven, IL-6-mediated prerenal/hemodynamic AKI as ide-cel, with tumor-lysis crystal nephropathy in high-burden disease. The notable distinct toxicity is delayed neurotoxicity — a movement/neurocognitive (parkinsonism-like) syndrome hypothesized to relate to basal-ganglia BCMA expression — which is not renal but a hallmark management concern.
Clinical presentation
CRS often has a slightly later onset than ide-cel (median ~7 days), with AKI tracking CRS. A delayed parkinsonism/movement disorder can emerge weeks after infusion, frequently after ICANS.
Onset
AKI in the first 1-2 weeks; the movement disorder is delayed (weeks).
Reversibility
Reversible
Anticancer mechanism
Autologous BCMA-directed CAR-T bearing two BCMA-binding single-domain antibodies (bivalent) with 4-1BB and CD3-zeta domains, giving high avidity for BCMA on myeloma cells and driving T-cell activation and plasma-cell killing.
Management
Tocilizumab with or without corticosteroids for CRS, plus hemodynamic/renal support and standard tumor-lysis management (rasburicase, allopurinol, hydration). For parkinsonism, dopaminergic regimens have been reported; the movement disorder is often refractory to immunosuppression.
Risk factors
- High tumor burden
- High-grade CRS/ICANS
- Prior transplant
- Baseline CKD
Prevention
- Tumor-lysis prophylaxis (hydration, allopurinol/rasburicase)
- Close CRS/ICANS monitoring
- Nephrotoxin avoidance and renal dosing of fludarabine conditioning
- Prolonged neurologic surveillance for the delayed movement disorder
Note · Frontier-era 2022 therapy; renal mechanism is shared BCMA CAR-T CRS-driven prerenal AKI, with the distinctive delayed movement disorder flagged for differential awareness.
Clinical depth
Renal dose adjustment
A fixed cell product with no renal dose adjustment; renal dosing applies to the lymphodepleting fludarabine.
Dialyzability & ESKD dosing
Not applicable (a living-cell product). Dialysis supports AKI/tumor lysis rather than removing the therapy.
Differential diagnosis
CRS-prerenal AKI versus tumor lysis versus ATN versus fludarabine nephrotoxicity; and for neurologic decline, ICANS versus the delayed parkinsonism — do not attribute late neuro changes to uremia.
Monitoring
- Daily renal, electrolyte and tumor-lysis labs during CRS
- CRS/ICANS grading (ASTCT criteria)
- Prolonged neurologic monitoring for the delayed movement disorder
Key trials & series
- CARTITUDE-1 (Berdeja, Lancet 2021) — pivotal phase 1b/2 registrational trial
- CARTITUDE-4 (San-Miguel, NEJM 2023) — randomized trial supporting earlier-line use
Clinical pearls
- Cilta-cel shares CAR-T renal physiology with ide-cel — AKI is CRS/IL-6-mediated and mostly prerenal.
- The signature unique toxicity is delayed parkinsonism; renal teams should not attribute late neurologic decline to uremia.
- Tumor-lysis risk is highest with bulky disease.
- AKI generally reverses with supportive care as CRS resolves.
Where it strikes
Nephron segments
Vasculature / Endothelium
Glomerular & peritubular capillaries
Tubular Lumen
The urine flow path
Injury signatures
Prerenal / Hemodynamic AKIAcute Tubular NecrosisElectrolyte Wasting
Beyond the kidney
Class-level context for the major non-renal toxicities of bcma car-t cell therapys.
Immune / Infusion
CRS, infusion reactions, irAEs, anaphylaxis
- Cytokine release syndrome
Neurologic
Neuropathy, encephalopathy, ICANS, PRES
- ICANS / neurotoxicity
Hematologic
Cytopenias, thrombosis, TMA
- Cytopenias, hypogammaglobulinemia
Evidence
6 peer-reviewed references. Citation metadata via PubMed / NLM.
LandmarkCiltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.Berdeja JG et al. · Lancet 2021 · PMID 34175021CARTITUDE-1 pivotal registrational trial.PMIDCiltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up.Martin T et al. · J Clin Oncol 2022 · PMID 35658469CARTITUDE-1 2-year durability/safety follow-up.PMIDCilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma.San-Miguel J et al. · N Engl J Med 2023 · PMID 37272512CARTITUDE-4 randomized trial supporting earlier-line use.PMIDAcute Kidney Injury after CAR-T Cell Therapy: Low Incidence and Rapid Recovery.Gutgarts V et al. · Biol Blood Marrow Transplant 2020 · PMID 32088364CAR-T AKI cohort (incidence, CRS link, recovery) applicable to BCMA CAR-T.PMIDChemotherapy-induced reversal of ciltacabtagene autoleucel-associated movement and neurocognitive toxicity.Graham CE et al. · Blood 2023 · PMID 37467494Real-world cilta-cel delayed parkinsonism/movement toxicity.PMIDCAR T-cell therapy and the onco-nephrologist.Salvino MA et al. · Front Nephrol 2024 · PMID 38706889Onconephrology review of CAR-T renal complications.
Related agents
Other agents sharing the same signature kidney injury.